Clinical Trial Detail

NCT ID NCT02880371
Title A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Array BioPharma
Indications

melanoma

stomach cancer

colorectal cancer

triple-receptor negative breast cancer

lung non-small cell carcinoma

urinary bladder cancer

head and neck squamous cell carcinoma

ovarian cancer

pancreatic ductal adenocarcinoma

Therapies

ARRY-382 + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST